Avita Medical Inc (RCEL) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Avita Medical Inc   (NASDAQ: RCEL)

Select the Financial Report: Select the Period:


Description of Avita Medical Inc's Business Segments


Avita Medical Inc. is a biotechnology company that focuses on developing and commercializing regenerative medicine products. Their primary aim is to offer innovative solutions for wound care and scar management. Below is an extensive description of the segments, products, and services offered by Avita Medical.

Segments

1. Wound Care
- Avita Medical primarily operates in the wound care segment, addressing conditions such as chronic and acute wounds. This includes diabetic ulcers, pressure ulcers, venous ulcers, and surgical wounds. The company emphasizes the need for effective treatments that enhance healing and reduce complications associated with these injuries.

2. Scar Management
- Another critical segment for Avita Medical involves products aimed at improving outcomes in scar management. This includes both hypertrophic scars and keloids that may result from various injuries or surgical procedures. The company’s innovative solutions aim to reduce the size, appearance, and discomfort typically associated with scars.

3. Regenerative Medicine
- Avita Medical is at the forefront of regenerative medicine, focusing on therapies that harness the body’s inherent healing mechanisms. By promoting tissue regeneration and repair, their products aim to provide a more natural healing process compared to traditional treatments.

Products

1. RECELL® System
- The RECELL® System is Avita Medicals flagship product, designed to treat wounds and scars. It utilizes a unique process that involves harvesting a small amount of skin from a patient, which is then processed to create a suspension of viable cells. This suspension can be applied directly to the wound or scar, promoting faster healing and improved aesthetic outcomes.
- The RECELL® System is FDA-approved and has received widespread endorsement due to its innovative approach to wound healing. It is used in various clinical settings, including hospitals and specialized dermatology clinics.

2. Product Applications
- The RECELL® System is indicated for use in a range of applications, including:
- Burn Treatment: Effective for acute burn wounds, allowing for rapid coverage and healing.
- Chronic Wound Management: Applied in difficult-to-heal wounds, such as diabetic foot ulcers and venous stasis ulcers.
- Scar Treatment: Used to address hypertrophic scars and keloids, focusing on both functional and cosmetic outcomes.

3. Investigational Products
- Avita Medical has a pipeline of investigational products currently under development. These may include extensions of the RECELL® technology for additional indications, such as other types of difficult-to-heal wounds or novel applications in regenerative medicine.

Services

1. Training and Support
- Avita Medical provides comprehensive training programs for healthcare professionals. This includes workshops, webinars, and in-service training sessions designed to educate clinicians on the proper use of the RECELL® System and best practices in wound management.
- Ongoing customer support is also a critical component, ensuring that medical personnel can effectively integrate Avita’s products into their treatment protocols.

2. Clinical Research and Collaborations
- Avita Medical actively engages in clinical research to validate the efficacy and safety of their products. This includes collaborations with hospitals, universities, and research institutions to conduct studies that contribute to the scientific understanding of regenerative medicine.
- The company may also participate in clinical trials to explore new applications of their existing technologies and push the boundaries of wound care practices.

3. Regulatory and Compliance Assistance
- Given the stringent regulatory environment in the biotechnology and medical device sectors, Avita Medical offers support to healthcare providers in navigating compliance issues related to the use of their products. This includes providing guidance on documentation, billing, and insurance reimbursement processes.

Conclusion

Avita Medical Inc. is a pioneering company in the fields of wound care, scar management, and regenerative medicine. They offer innovative products like the RECELL® System and provide extensive training and support services for healthcare professionals. Through their commitment to research and collaboration, Avita Medical continues to advance the field of wound healing and improve the quality of care available to patients suffering from complex wounds and scars.


Composition of Avita Medical Inc Revenues by Segments

 
Recell Go Preparation Kit    92.16 % of total Revenue
US    181.62 % of total Revenue
JP    3.81 % of total Revenue
United Kingdom    1.84 % of total Revenue
Recell System    166.67 % of total Revenue
Cohealyx    14.95 % of total Revenue
PermeaDerm    4.8 % of total Revenue

Q2 three months ended (Jun 30 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
Recell Go Preparation Kit 20.00 92.16 %
US 39.42 181.62 %
JP 0.83 3.81 %
United Kingdom 0.40 1.84 %
Recell System 36.17 166.67 %
Cohealyx 3.24 14.95 %
PermeaDerm 1.04 4.8 %
Total 21.70 100 %




Q2 three months ended (Jun 30 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Recell Go Preparation Kit - -
US - -
JP - -
United Kingdom 627.27 % 98.02 %
Recell System - -
Cohealyx - -
PermeaDerm - -
Total 17.83 % 12.73 %




Q2 three months ended (Jun 30 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Total -7.66 -




Q2 three months ended (Jun 30 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Total - -




Annual Report on Avita Medical Inc Divisions, Sales by Country

 
United Kingdom   United Kingdom Segment contribution to total sales 0.68 % of total Revenue
PermeaDerm   PermeaDerm Segment contribution to total sales 8.38 % of total Revenue
RPK   RPK Segment contribution to total sales 49.99 % of total Revenue
Commercial Sales   Commercial Sales Segment contribution to total sales 99.76 % of total Revenue
Commercial Sales RECELL   Commercial Sales RECELL Segment contribution to total sales 92.81 % of total Revenue
Commercial Sales Other Wound Care Products   Commercial Sales Other Wound Care Products Segment contribution to total sales 5.93 % of total Revenue
Commercial Sales Lease Revenue   Commercial Sales Lease Revenue Segment contribution to total sales 1.02 % of total Revenue
Deferred Commercial Revenue Recognized   Deferred Commercial Revenue Recognized Segment contribution to total sales 0.05 % of total Revenue
United States   United States Segment contribution to total sales 96.06 % of total Revenue
Japan   Japan Segment contribution to total sales 2.92 % of total Revenue
Australia   Australia Segment contribution to total sales 0.28 % of total Revenue
BARDA Revenue For Right of First Access   BARDA Revenue For Right of First Access Segment contribution to total sales 0.19 % of total Revenue
European Union   European Union Segment contribution to total sales 0.07 % of total Revenue


Twelve months ended 2025
RCEL s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
United Kingdom 0.49 0.68 %
PermeaDerm 6.00 8.38 %
Total 71.61 100 %
RPK 35.80 49.99 %
Commercial Sales 71.44 99.76 %
Commercial Sales RECELL 66.46 92.81 %
Commercial Sales Other Wound Care Products 4.25 5.93 %
Commercial Sales Lease Revenue 0.73 1.02 %
Deferred Commercial Revenue Recognized 0.03 0.05 %
United States 68.79 96.06 %
Japan 2.09 2.92 %
Australia 0.20 0.28 %
BARDA Revenue For Right of First Access 0.14 0.19 %
European Union 0.05 0.07 %


Twelve months ended 2025
RCEL s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total -48.59 -

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
United Kingdom 147.96 % -
Total 11.45 % -
RPK 104.57 % -
Commercial Sales 11.58 % -
Commercial Sales RECELL 6.15 % -
Commercial Sales Other Wound Care Products 302.85 % -
Commercial Sales Lease Revenue 104.19 % -
Deferred Commercial Revenue Recognized 0 % -
United States 10.67 % -
Japan 45.91 % -
Australia -35.9 % -
BARDA Revenue For Right of First Access -28.72 % -
European Union -68.39 % -
Commercial Cost - -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.